



Published in final edited form as:

*Breast Cancer Res Treat.* 2013 August ; 140(3): 485–494. doi:10.1007/s10549-013-2655-2.

## Defining a threshold for intervention in breast cancer-related lymphedema: What level of arm volume increase predicts progression?

Michelle C Specht, MD<sup>1</sup>, Cynthia L Miller, BS<sup>2</sup>, Tara A Russell, MPH<sup>2</sup>, Nora Horick, MS<sup>3</sup>, Melissa N Skolny, MSHAS<sup>2</sup>, Jean A O'Toole, PT, MPH<sup>4</sup>, Lauren S Jammallo, BS<sup>2</sup>, Andrzej Niemierko, PhD<sup>2</sup>, Betro T Sadek, MD<sup>2</sup>, Mina N Shenouda, MD<sup>2</sup>, Dianne M Finkelstein, PhD<sup>3</sup>, Barbara L Smith, MD, PhD<sup>1</sup>, and Alphonse G Taghian, MD, PhD<sup>2</sup>

<sup>1</sup>Division of Surgical Oncology, Massachusetts General Hospital

<sup>2</sup>Department of Radiation Oncology, Massachusetts General Hospital

<sup>3</sup>Department of Biostatistics, Massachusetts General Hospital

<sup>4</sup>Department of Physical and Occupational Therapy, Massachusetts General Hospital

### Abstract

**Purpose**—Evaluate arm volume measurements and clinico-pathologic characteristics of breast cancer patients to define a threshold for intervention in breast cancer-related lymphedema.

**Methods**—We prospectively performed arm volume measurements on breast cancer patients using a Perometer. Arm measurements were performed pre- and post-operatively, and change in arm volume was quantified using a relative volume change (RVC) equation. Patient and treatment risk factors were evaluated. Cox proportional hazards models with time-dependent covariates for RVC were used to evaluate whether RVC elevations of 3%–<5% or 5%–<10% occurring 3 months or >3 months after surgery were associated with progression to 10% RVC.

**Results**—1173 patients met eligibility criteria with a median of 27 months post-operative follow-up. The cumulative incidence of 10% RVC at 24 months was 5.26% (95% CI: 4.01% – 6.88%). By multivariable analysis, a measurement of 5%–<10% RVC occurring >3 months after surgery was significantly associated with an increased risk of progression to 10% RVC (HR: 2.97,  $p < 0.0001$ ), but a measurement of 3%–<5% RVC during the same time period was not statistically significantly associated (HR: 1.55,  $p = 0.10$ ). Other significant risk factors included a measurement 3 months after surgery with RVC of 3%–<5% ( $p = 0.007$ ), 5%–<10% ( $p < 0.0001$ ), or 10% ( $p = 0.023$ ), axillary lymph node dissection (ALND) ( $p < 0.0001$ ), and higher BMI at diagnosis ( $p = 0.0028$ ). Type of breast surgery, age, number of positive or number of lymph nodes removed, nodal radiation, chemotherapy, and hormonal therapy were not significant ( $p > 0.05$ ).

**Conclusion**—Breast cancer patients who experience a relative arm volume increase of 3%–<5% occurring >3 months after surgery do not have a statistically significant increase in risk of progression to 10%, a common lymphedema criterion. Our data supports utilization of a 5%–<10% threshold for close monitoring or intervention, warranting further assessment. Additional

---

**Corresponding Author Contact Information:** Alphonse G. Taghian, MD PhD, 100 Blossom Street, Boston, MA 02114. Tel: 617-726-6050, Fax: 617-726-3603, ataghian@partners.org.

**Financial Disclosures:** The authors have no financial disclosures to report.

### DISCLOSURES

The authors have no conflicts of interest to disclose.

risk factors for progression to 10% include ALND, higher BMI, and post-operative arm volume elevation.

### Keywords

Lymphedema; Quality of Life; Compression Therapy; Threshold; Early Intervention

---

## INTRODUCTION

Survival rates after treatment for breast cancer are high, making attention to quality of life and long-term effects of treatment increasingly important[1–3]. Lymphedema is a chronic condition characterized by swelling of the arm, hand, breast, or trunk, which may develop as a result of breast cancer treatment from an accumulation of lymphatic fluid in the interstitial tissues. It is known to have detrimental effects on quality of life due to body image changes, alterations in arm function, and increased complications such as infection and cellulitis[2,4–6].

Although reported incidence rates vary, a recent meta-analysis indicated that more than 1 in 5 breast cancer patients will develop lymphedema[7]. The most commonly cited risk factors for breast cancer-related lymphedema include axillary lymph node dissection (ALND)[7–16], and high Body Mass Index (BMI) or obesity[7,10,13,15,16–25]. A number of other risk factors have been suggested, including mastectomy[5,7,13,14,21], extent of axillary surgery[7,15,22,23,26–28], number of pathologically involved lymph nodes[14,15,21,24,29], chemotherapy[8,10,15,22,29], nodal radiation[13,14,22,24,25,28,30–34], age[5,12,17,27,31,33], and physical activity levels[5,7,13].

In an effort to decrease the physical and psychosocial complications of lymphedema, it is increasingly recommended that patients should be screened for low-level arm volume changes to enable early intervention[4,35–37]. The National Lymphedema Network recommends pre-operative assessment and ongoing surveillance for lymphedema as “imperative” and “best practice”[38]. However, the appropriate threshold for intervention when volume changes occur has not been adequately defined.

Varying definitions and methods of measurement for lymphedema have been utilized[37,39,40]. An absolute difference between arms or increase from pre-operative baseline in the at-risk arm of > 2 cm circumference by tape measurement or >200 ml volume by water displacement or perometry is often considered indicative of lymphedema[7,14,41]. In addition, a relative volume difference between arms or increase in at-risk arm volume from pre-operative baseline of 5–10% by perometry, water displacement, or circumferential tape measurement may be used to define lymphedema[7,14,39,41,42]. Bioimpedance spectroscopy (BIS) is a newer technique which measures extracellular fluid of the upper extremity, with a corresponding lymphedema criterion based on the impedance ratio between arms or change from a pre-operative baseline outside of a normal range[43].

The quantification of lymphedema by the Perometer has been rigorously validated, demonstrating high accuracy and overall reliability across repeated measurements[44,45]. We previously reported that accurate evaluation for lymphedema must include a pre-operative measurement and account for changes in the at-risk and contralateral arm, and developed the relative volume change (RVC) equation[46]. Although prior studies have defined lymphedema as a volume increase of >3%–15%[7,14], the majority have utilized >10% as a lymphedema criterion[21,33,41,47–55]. In addition, a 2009 study by Cormier et al found that >10% volume change was an independent risk factor for decreased quality of

life[42]. Therefore in the clinical setting at our institution and for the purpose of this study, we chose to utilize 10% RVC as an endpoint for progression.

In a 2008 report, Stout-Gergich et al. proposed four stages for evaluating early lymphedema based on volume change measured via perometry: 0–3% - At Risk for Lymphedema, 3–5% - Pre-Clinical Lymphedema, 5–8% - Mild Lymphedema and, >8% -Moderate-Severe Lymphedema[36]. Based on their findings, the authors advocated that an arm volume increase of >3% is an appropriate threshold for intervention with compression therapy.

We sought to determine whether utilization of 3–<5% or 5–<10% RVC thresholds prognosticate progression to 10% RVC by analyzing arm volume measurements for patients prospectively screened for lymphedema at our institution. Arm volume measurements, patient demographics and treatment characteristics were analyzed to identify risk factors for progression to 10% RVC.

## MATERIAL & METHODS

Beginning in 2005, with Institutional Review Board approval, we prospectively obtained bilateral arm volume measurements on women diagnosed with breast cancer using a Perometer. Measurements were obtained pre- and post-operatively, during treatment for breast cancer, and at follow-up oncology visits after completion of breast cancer treatment. The protocol for lymphedema screening and the equation for relative volume change (RVC) have previously been published[46]. Briefly,  $RVC = [(A_2U_1) / (U_2A_1)] - 1$  where  $A_1$ ,  $A_2$  are arm volumes on the side treated for breast cancer at pre-operative baseline and a post-operative follow-up, and  $U_1$ ,  $U_2$  are arm volumes on the contralateral side at the corresponding time points. The RVC equation accounts for pre-operative asymmetry between arms, and incorporates contralateral arm volume to account for changes in arm size caused by factors unrelated to lymphedema, such as weight gain. Any measurements obtained after a patient was diagnosed with distant metastasis or recurrence were excluded to avoid potential confounding. Patients who underwent bilateral breast or axillary surgery were excluded entirely from the analysis, since the RVC formula cannot be used for patients at risk for bilateral lymphedema.

For this analysis, patients underwent a pre-operative measurement between 08/2005 – 08/2012, and received surgery and follow-up care at our institution for primary breast cancer. All patients had a pre-operative measurement and at least one follow-up measurement occurring >3 months after surgery. A measurement with 10% RVC occurring >3 months after surgery was utilized as the endpoint for analysis of arm volume progression. Once a patient underwent a measurement with 10% RVC (>3 months post-operative), all further measurements for that patient were excluded from the analysis.

To determine whether low-level RVC elevation is associated with progression to 10% RVC, patients were categorized according to whether they had an RVC in the 3–<5% and / or 5–<10% range at a measurement >3 months after surgery. Measurements occurring 3 months post-operative were categorized similarly (with an additional category of 10% RVC) and considered as independent risk factors in the analysis. Any measurements occurring after a patient initiated lymphedema treatment with compression therapy were excluded from analysis in order to analyze the natural history of arm volume progression without the influence of treatment intervention. Medical record review was used to determine which patients received treatment and defined by prescription for a compression sleeve.

Patient demographics, surgical, radiation and medical oncology treatments were collected via medical record review to analyze as risk factors. Nodal radiation was defined as radiation to the breast/chest wall with supraclavicular and/or axillary radiation.

We used Cox proportional hazards regression to evaluate whether an RVC of 3%–<5% and/or 5%–<10% occurring >3 months after surgery was associated with progression to 10% RVC. The time from surgery to 10% RVC ("event") or most recent follow-up RVC measurement ("censored") was used as the time-to-event variable in the Cox models. Thus estimates are adjusted for the amount of follow-up time, as only patients with comparable follow-up are included in each risk set. Separate time-dependent covariates for RVC measurements in the range of 3%–<5% and 5%–<10% were used such that patients were included in the non-elevated category until their first RVC in the 3%–<5% or 5%–<10% category occurred. Therefore a patient categorized in the 3%–<5% RVC group who progressed to 5%–<10% RVC before crossing RVC 10% was considered in both groups when analyzing for progression.

Separate covariates were included for RVC categories of 3%–<5%, 5%–<10%, and 10% occurring 3 months after surgery. A small fraction of patients did not have a measurement within 3 months of surgery, and were included in the <3% reference category. Models were also run with these patients excluded to assess the impact on results. Patient and treatment risk factors were evaluated, and the number of measurements per year was included in the multivariable regression to account for variation in the frequency of measurements among patients. The Kaplan-Meier method was used to obtain estimates of cumulative incidence of 10% RVC occurring >3 months after surgery[56]. The cumulative incidence of progression to 10% RVC was calculated among patients who had a measurement in the 3%–<5% RVC category, where the starting point for assessment of progression was the patient's initial measurement in the 3%–<5% category after 3 months post-operative. Similarly, the cumulative incidence of progression to 10% RVC was calculated among those with a measurement in the 5%–<10% RVC category occurring >3 months after surgery.

## RESULTS

### Patient population

1173 patients met eligibility. The median post-operative follow-up was 26.9 months (range: 3.3 – 82.6, 25<sup>th</sup> percentile: 15.2, 75<sup>th</sup> percentile: 43.9). Median number of measurements per patient was 6 (range: 2–21, 25<sup>th</sup> percentile: 4, 75<sup>th</sup> percentile: 8). Clinical and pathologic characteristics of the study population are presented in Table 1. The cumulative incidence of 10% RVC occurring >3 months after surgery was 5.26% (95% CI: 4.01% – 6.88%) at 24 months and 9.75% (95% CI: 7.62% – 12.4%) at 48 months post-operative (Figure 1). The median time to crossing 10% RVC (>3 months post-operative) was 14.4 months (range: 3.5 – 57.1). 5% (57/1173) of patients received treatment for lymphedema with compression therapy. Of these patients, 5 had a maximum RVC of <5%, 25 had a maximum RVC of 5–<10% and 27 patients had a maximum RVC of 10% prior to treatment initiation.

### Risk of progression to ≥10% RVC by patient / treatment factors

Patients who underwent ALND with nodal radiation had the highest 2-year cumulative incidence at 18.1%, compared to 6.1% for sentinel lymph node biopsy (SLNB) with nodal radiation. The cumulative incidence of 10% RVC was 2.0% for patients who underwent SLNB without nodal radiation, and 2.4% for no axillary surgery (Table 2). Factors significant for increased risk of progression to 10% RVC at >3 months after surgery by univariate analysis are included in Table 3. By multivariable analysis, ALND ( $p<0.0001$ ) and higher BMI at diagnosis ( $p=0.0028$ ) were the only patient/treatment factors significantly

associated with an increased risk of progression to 10% RVC at >3 months after surgery (Table 4).

### **Risk of progression to $\geq 10\%$ RVC by levels of arm volume increase occurring >3 months post-operative**

Among patients who had an RVC measurement in the 3%–<5% category occurring >3 months after surgery, the cumulative incidence of progression to 10% RVC was 10.8% (95% CI: 7.1%–16.1%) at 24 months after the first measurement in the 3%–<5% range. Among those who had an RVC of 5%–<10%, the comparable estimate of cumulative incidence of progression was 18.7% (95% CI: 12.6%–27.4%) (Figure 2). By multivariable analysis, a measurement of 5%–<10% RVC occurring >3 months after surgery was statistically significantly associated with an increased risk of progression to 10% RVC ( $p < 0.0001$ ), but a measurement of 3%–<5% RVC during this time period was not statistically significant ( $p = 0.10$ ) (Table 4). The number of measurements per year was also significantly associated with increased risk of progression to 10% RVC by multivariable analysis ( $p < 0.0001$ ).

### **Risk of progression to $\geq 10\%$ RVC by levels of arm volume increase occurring $\leq 3$ months post-operative**

95% (1120/1173) of patients had a measurement 3 months after surgery. Of these patients, 8.4% (94/1120) had an RVC of 3%–<5%, 7.1% (79/1120) had an RVC of 5%–<10%, and 1.3% (14/1120) had an RVC of 10% within 3 months of surgery. The remaining 933 patients (83.3%) had an RVC of <3% during this time period. By multivariable analysis, all three categories of RVC elevation occurring 3 months after surgery were significantly associated with an increased risk of progression to 10% RVC (Table 4). A multivariable model excluding the 53 patients without a measurement within 3 months of surgery demonstrated similar results (data not shown).

## **DISCUSSION**

To our knowledge, the current study represents the largest cohort of breast cancer patients prospectively screened for lymphedema using the Perometer, a highly accurate tool with demonstrated validity in quantifying arm volume. In our analysis of 1173 patients, a measurement of 5%–<10% RVC, higher BMI at diagnosis, and ALND were associated with a statistically significant increase in risk of progression to 10% RVC by multivariable analysis. A measurement of 3%–<5% RVC was significant for progression to 10% RVC when it occurred within 3 months of surgery, but did not reach statistical significance at a time >3 months post-operative. Interestingly, any range of RVC elevation occurring 3 months after surgery was significantly associated with increased risk of progression to 10% RVC. Our findings support utilization of a 5%–<10% threshold for close monitoring or intervention. Further assessment of this strategy is warranted.

Screening programs for early detection and intervention in breast cancer-related lymphedema have been recommended[35,36,38], but an appropriate threshold for intervention has not yet been determined. The emotional and financial burden of lymphedema treatment is well-documented[8,57], as is the importance of early intervention aimed at preventing progression of this condition[40,58,59]. It is therefore critical that an effective threshold for intervention be established.

A prior study by Stout-Gergich et al. utilized compression therapy at >3% increase in arm volume to assess the effectiveness of early intervention[36]. In this single arm, Phase II study, 43 breast cancer patients who developed an arm volume increase of >3% received



intervention with compression therapy. In the follow-up period after intervention (mean 4.8 months), a greater decrease in absolute arm volume was reported in patients who received intervention compared to an age-matched control group. The study did not have a randomized-controlled design. Based on their results, the authors proposed that >3% arm volume increase is a diagnostic criterion for subclinical lymphedema and recommended intervention at that threshold.

Our data suggest that a measurement of 3%–<5% RVC is statistically significant for progression to 10% RVC only when it occurs within 3 months of surgery, and not at later time points. While Stout-Gergich et al. reported reduced arm volume in patients who initiated compression therapy after reaching >3% [36], it is unclear that such intervention was warranted. The median time to development of >3% in their trial was 6.9 months post-operative, and based on our data it is likely that some patients would not otherwise have progressed to 10%, a common lymphedema criterion, had they not received intervention.

In contrast, our data suggests that a 5%–<10% RVC criterion may be a better threshold for early intervention, as crossing this threshold at any time following surgery was a significant predictor of progression to 10% RVC. The cumulative incidence of progression to 10% for patients with an RVC of 5%–<10% occurring >3 months after surgery was 18.7%, compared with 10.8% for 3%–<5% during this period. Furthermore, recent reports have suggested that arm volume increases in the range of 5–10% may represent low-level edema based on lymphedema symptoms reported by patients with volume changes in this range [42,60]. It should be noted that the confidence intervals for cumulative incidence of progression for patients with a measurement of 3%–<5% and 5%–<10% in our series overlap, warranting further investigation. We are currently conducting a prospective, randomized-controlled trial of compression therapy versus observation in patients with a measurement of 5%–<10% RVC to evaluate the efficacy of intervention at this threshold [Clinical Trials.gov Identification number NCT00959985] [61].

In our series, a measurement of 3%–<5% RVC occurring within 3 months of surgery was significant for increased risk of progression to 10% RVC, but was not statistically significant when it occurred later in follow-up (>3 months post-operative). We did find that patients with a measurement of 3%–<5% occurring >3 months after surgery had a 10.8% risk of progression to 10% RVC. Given these findings, we suggest that patients with a measurement of 3%–<5% RVC any time after surgery undergo close monitoring with a re-measurement at 1–2 months to assess for progression.

Consistent with prior reports, independent clinico-pathologic risk factors for progression to 10% RVC in our series included ALND and higher BMI at diagnosis [7–16]. We did not find type of breast surgery, extent of axillary surgery, number of pathologically involved lymph nodes, chemotherapy, or nodal radiation to be significant for progression to 10% RVC by multivariate analysis. These have less commonly been cited as risk factors for lymphedema, with the majority lacking strong evidence from prospective studies utilizing accurate measurement techniques. Interestingly, we found that the rate of 10% RVC in patients with no axillary surgery was 2.4%, which was similar to the 2.0% incidence for SLNB without nodal radiation. These findings suggest that while patients who undergo SLNB are at risk for developing lymphedema (albeit low), this risk may not be significantly greater than for patients without axillary surgery.

We also found that a measurement of 3%–<5%, 5%–<10%, or 10% RVC within 3 months of surgery was significantly associated with an increased risk of progression to 10% RVC. Furthermore, increasingly higher categories of RVC elevation during this period represented a more significant risk of progression. Mahamaneerat et al also demonstrated the importance

of post-operative arm volume elevation as a risk factor for lymphedema, reporting that a 5% increase in arm volume 1 month after surgery was associated with a 1.4-fold increased risk of lymphedema[62]. These findings demonstrate the importance of screening within 3 months of surgery, such that patients with elevated arm volume during this period can be closely monitored for future progression.

The 2-year cumulative incidence of 10% RVC in our series was 6.1% for patients who underwent SLNB with nodal radiation and 2.0% for SLNB without, compared to 18.1% for ALND with and 10.2% for ALND without nodal radiation. McLaughlin et al. similarly reported a 5% incidence for patients with SLNB and 16% for those with ALND[16]. Other studies have reported significantly higher rates of lymphedema compared to our series, ranging as high as 30–80% [5,63–66]. The incidence of 10% RVC in our cohort may be lower than lymphedema rates reported in previous studies due to differences in length of follow-up, method of measurement and definition of lymphedema. We chose to report cumulative incidence at 2 years (rather than 4 or 5 years) based on our median follow up of 26.9 months. In addition, we excluded measurements occurring after initiation of compression therapy, which may underestimate the incidence of 10% RVC in our cohort. However, the exclusion of measurements obtained after initiation of treatment uniquely enabled us to analyze the natural history of arm volume progression as it occurs without the influence of treatment intervention.

New cases of lymphedema continued to appear up to 4 years after surgery in our series, with cumulative incidence increasing from 5.3% to 9.8% at 2 to 4 years. Although some have reported that lymphedema most commonly occurs within 2 years of diagnosis[7], others have shown that incidence continues to increase throughout follow-up[63,67]. Petrek et al demonstrated that lymphedema developed at >3 years in 25% of patients, with an ongoing risk of approximately 1% per year for at least 20 years[67]. In another study, Norman et al reported that 20% of lymphedema cases occurred between 2–5 years[63]. These findings support screening for lymphedema both during and after completion of breast cancer treatment.

Our study is limited by the variable time intervals at which patients underwent arm volume measurements. Patients were measured at their routine oncology follow-up visits, raising the possibility that transient episodes of arm volume elevation may have been missed between measurements. This may underestimate the number of patients who developed 10% RVC, and the number who met an RVC threshold and subsequently underwent regression of arm volume. There may also have been a bias of greater frequency of screening for patients with lymphedema symptoms or those perceived to be at high-risk for lymphedema, as reflected by the association of number of measurements per year with progression to 10% RVC in the multivariable model. A prospective study with pre-specified time intervals for follow-up measurements is underway to address this issue [ClinicalTrials.gov Identification number NCT00959985][61]. Finally, our study is limited by variable use of lymphedema treatments, as the decision to treat using compression therapy was left to the patient and clinician. As a result, we may be under- or over-estimating the risk of arm volume progression since measurements occurring after initiation of compression therapy were excluded from analysis.

Lymphedema continues to be one of the most-feared complications of breast cancer treatment. Our study provides new insights into the natural history of arm volume progression in breast cancer patients, and suggests use of specific thresholds for intervention. In addition, we identify independent risk factors for arm volume progression which can be utilized to target high-risk patients for close monitoring. Based on our results,

we propose a revised approach for classification of, and intervention for, arm volume elevation which may occur in breast cancer patients.

- 3%-<5% RVC – close monitoring with repeat arm volume measurement within 1–2 months.
- 5%-<10% RVC – randomization into a prospective trial of observation versus treatment with compression therapy. For patients not participating in a clinical trial, close monitoring with a repeat arm volume measurement within 1–2 months
- 10% RVC – treatment with compression therapy or other methods at the discretion of the healthcare provider.

In conclusion, our data suggests that an increase in arm volume of 5%-<10% may represent an appropriate threshold for intervention to prevent progression to 10%, a common criterion for lymphedema. An arm volume increase of 3%-<5% occurring >3 months after surgery is not statistically significant for increased risk of progression to 10%, and therefore may be insufficient to warrant intervention. We found that patients who undergo ALND, have a high BMI at diagnosis, or experience an elevated RVC within 3 months of surgery had an increased risk of progression to 10%, suggesting the importance of close monitoring for these patients. Further research is warranted to determine the efficacy of early intervention with compression therapy for patients with an arm volume increase of 5%-<10%. In addition, future studies should address the impact of such interventions on quality of life compared with the benefit of preventing lymphedema development.

## Acknowledgments

This project was supported by Award R01CA139118 (AGT), and Award P50CA089393 (AGT) from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institutes of Health. In addition, we would like to acknowledge Nadine R. Taghian, whose dedication helped expedite completion of this project. The authors are greatly appreciative of her efforts.

## REFERENCES

1. Khan F, Amatya B, Pallant JF, Rajapaksa I. Factors associated with long-term functional outcomes and psychological sequelae in women after breast cancer. *Breast*. 2012; (3):314–320. [PubMed: 22342676]
2. Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR. Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. *J Clin Oncol*. 2008; 26(35):5689–5696. [PubMed: 19001331]
3. Rief W, Bardwell WA, Dimsdale JE, Natarajan L, Flatt SW, Pierce JP. Long-term course of pain in breast cancer survivors: a 4-year longitudinal study. *Breast Cancer Res Treat*. 2011; 130(2):579–586. [PubMed: 21656272]
4. Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. *Surg Oncol*. 2006; 15(3):153–165. [PubMed: 17187979]
5. Hayes SC, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. *J Clin Oncol*. 2008; 26(21):3536–3542. [PubMed: 18640935]
6. Jager G, Doller W, Roth R. Quality-of-life and body image impairments in patients with lymphedema. *Lymphology*. 2006; 39(4):193–200. [PubMed: 17319632]
7. Disipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *Lancet Oncol*. 2013; 14(6):500–515. [PubMed: 23540561]




8. Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, Perkins GH, Elting LS. Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study. *J Clin Oncol.* 2009; 27(12):2007–2014. [PubMed: 19289624]
9. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnott DH, Fleissig A, Clarke D, Ell PJ. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. *J Natl Cancer Inst.* 2006; 98(9): 599–609. [PubMed: 16670385]
10. Norman SA, Localio AR, Kallan MJ, Weber AL, Torpey HA, Potashnik SL, Miller LT, Fox KR, DeMichele A, Solin LJ. Risk factors for lymphedema after breast cancer treatment. *Cancer Epidemiol Biomarkers Prev.* 2010; 19(11):2734–2746. [PubMed: 20978176]
11. Yang EJ, Park WB, Seo KS, et al. Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors: a prospective cohort study. *J Surg Oncol.* 2010; 101(1):84–91. [PubMed: 19924721]
12. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. *J Clin Oncol.* 2007; 25(24):3657–3663. [PubMed: 17485711]
13. Park JH, Lee WH, Chung HS. Incidence and risk factors of breast cancer lymphoedema. *J Clin Nurs.* 2008; 17(11):1450–1459. [PubMed: 18482142]
147. Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. *Ann Surg Oncol.* 2009; 16(7):1959–1972. [PubMed: 19365624]
15. Ahmed RL, Schmitz KH, Prizment AE, Folsom AR. Risk factors for lymphedema in breast cancer survivors, the Iowa Women's Health Study. *Breast Cancer Res Treat.* 2011; 130(3):981–991. [PubMed: 21761159]
16. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, Hurley KE, Riedel ER, Van Zee KJ. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. *J Clin Oncol.* 2008; 26(32):5213–5219. [PubMed: 18838709]
17. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE 2nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. *Ann Surg Oncol.* 2006; 13(4):491–500. [PubMed: 16514477]
18. Soran A, Wu WC, Dirican A, Johnson R, Andacoglu O, Wilson J. Estimating the probability of lymphedema after breast cancer surgery. *Am J Clin Oncol.* 2011; 34(5):506–510. [PubMed: 21127413]
19. Swenson KK, Nissen MJ, Leach JW, Post-White J. Case-control study to evaluate predictors of lymphedema after breast cancer surgery. *Oncol Nurs Forum.* 2009; 36(2):185–193. [PubMed: 19273407]
20. Box RC, Reul-Hirche HM, Bullock-Saxton JE, Furnival CM. Physiotherapy after breast cancer surgery: results of a randomised controlled study to minimise lymphoedema. *Breast Cancer Res Treat.* 2002; 75(1):51–64. [PubMed: 12500934]
21. Nesvold IL, Dahl AA, Lokkevik E, Marit Mengshoel A, Fossa SD. Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. *Acta Oncol.* 2008; 47(5):835–842. [PubMed: 18568481]
22. Hayes SB, Freedman GM, Li T, Anderson PR, Ross E. Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation? *Int J Radiat Oncol Biol Phys.* 2008; 72(5):1449–1455. [PubMed: 19028274]
23. Paskett ED, Naughton MJ, McCoy TP, Case LD, Abbott JM. The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. *Cancer Epidemiol Biomarkers Prev.* 2007; 16(4):775–7782. [PubMed: 17416770]

24. Crosby MA, Card A, Liu J, Lindstrom WA, Chang DW. Immediate breast reconstruction and lymphedema incidence. *Plast Reconstr Surg*. 2012; 129(5):789e–795e. [PubMed: 22373982]
25. Ozaslan C, Kuru B. Lymphedema after treatment of breast cancer. *Am J Surg*. 2004; 187(1):69–72. [PubMed: 14706589]
26. Goldberg JI, Wiechmann LI, Riedel ER, Morrow M, Van Zee KJ. Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. *Ann Surg Oncol*. 2010; 17(12):3278–3286. [PubMed: 20574774]
27. Meeske KA, Sullivan-Halley J, Smith AW, McTiernan A, Baumgartner KB, Harlan LC, Bernstein L. Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. *Breast Cancer Res Treat*. 2008; 113(2):383–3291. [PubMed: 18297429]
28. Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphedema after primary treatment of breast carcinoma. *Cancer*. 2001; 92(7):1783–1787. [PubMed: 11745250]
29. Querci della Rovere G, Ahmad I, Singh P, Ashley S, Daniels IR, Mortimer P. An audit of the incidence of arm lymphoedema after prophylactic level I/II axillary dissection without division of the pectoralis minor muscle. *Ann R Coll Surg Engl*. 2003; 85(3):158–161. [PubMed: 12831486]
30. Deo SV, Ray S, Rath GK, Shukla NK, Kar M, Asthana S, Raina V. Prevalence and risk factors for development of lymphedema following breast cancer treatment. *Indian J Cancer*. 2004; 41(1):8–12. [PubMed: 15105573]
31. Graham P, Jagavkar R, Browne L, Millar E. Supraclavicular radiotherapy must be limited laterally by the coracoid to avoid significant adjuvant breast nodal radiotherapy lymphoedema risk. *Australas Radiol*. 2006; 50(6):578–582. [PubMed: 17107530]
32. Hayes S, Janda M, Cornish B, Battistutta D, Newman B. Lymphedema secondary to breast cancer: how choice of measure influences diagnosis, prevalence, and identifiable risk factors. *Lymphology*. 2008; 41(1):18–28. [PubMed: 18581955]
33. Asim M, Cham A, Banerjee S, Nancekivell R, Dutu G, McBride C, Cavanagh S, Lawrenson R, Campbell I. Difficulties with defining lymphoedema after axillary dissection for breast cancer. *N Z Med J*. 2012; 125(1351):29–39. [PubMed: 22426609]
34. Coen JJ, Taghian AG, Kachnic LA, Assaad SI, Powell SN. Risk of lymphedema after regional nodal irradiation with breast conservation therapy. *Int J Radiat Oncol Biol Phys*. 2003; 55(5):1209–1215. [PubMed: 12654429]
35. Boccardo FM, Ansaldo F, Bellini C, Accogli S, Taddei G, Murdaca G, Campisi CC, Villa G, Icardi G, Durando P, Puppo F, Campisi C. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. *Lymphology*. 2009; 42(1):1–9. [PubMed: 19499762]
36. Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. pre-operative assessment enables the early diagnosis and successful treatment of lymphedema. *Cancer*. 2008; 112(12):2809–2819. [PubMed: 18428212]
37. Armer JM. The problem of post-breast cancer lymphedema: impact and measurement issues. *Cancer Invest*. 2005; 23(1):76–83. [PubMed: 15779870]
38. National Lymphedema Network Medical Advisory Committee. Supplement to NLN position breast cancer screening: Screening and early detection of breast cancer-related lymphedema: The imperative. National Lymphedema Network; 2012.
39. Cheville AL, McGarvey CL, Petrek JA, Russo SA, Thiadens SR, Taylor ME. The grading of lymphedema in oncology clinical trials. *Semin Radiat Oncol*. 2003; 13(3):214–225. [PubMed: 12903011]
40. Petrek JA, Pressman PI, Smith RA. Lymphedema: current issues in research and management. *CA Cancer J Clin*. 2000; 50(5):292–307. [PubMed: 11075239]
41. Armer JM, Stewart BR. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. *Lymphat Res Biol*. 2005; 3(4):208–217. [PubMed: 16379589]
42. Cormier JN, Xing Y, Zaniletti I, Askew RL, Stewart BR, Armer JM. Minimal limb volume change has a significant impact on breast cancer survivors. *Lymphology*. 2009; 42(4):161–175. [PubMed: 20218084]

43. Cornish BH, Chapman M, Hirst C, Mirolo B, Bunce IH, Ward LC, Thomas BJ. Early diagnosis of lymphedema using multiple frequency bioimpedance. *Lymphology*. 2001; 34(1):2–11. [PubMed: 11307661]
44. Stanton AW, Northfield JW, Holroyd B, Mortimer PS, Levick JR. Validation of an optoelectronic limb volumeter (Perometer). *Lymphology*. 1997; 30(2):77–97. [PubMed: 9215977]
45. Tierney S, Aslam M, Rennie K, Grace P. Infrared optoelectronic volumetry, the ideal way to measure limb volume. *Eur J Vasc Endovasc Surg*. 1996; 12(4):412–417. [PubMed: 8980428]
46. Ancukiewicz M, Russell TA, Otoole J, Specht M, Singer M, Kelada A, Murphy CD, Pogachar J, Gioioso V, Patel M, Skolny M, Smith BL, Taghian AG. Standardized method for quantification of developing lymphedema in patients treated for breast cancer. *Int J Radiat Oncol Biol Phys*. 2011; 79(5):1436–1443. [PubMed: 20605339]
47. Celebioglu F, Perbeck L, Frisell J, Grondal E, Svensson L, Danielsson R. Lymph drainage studied by lymphoscintigraphy in the arms after sentinel node biopsy compared with axillary lymph node dissection following conservative breast cancer surgery. *Acta Radiol*. 2007; 48(5):488–495. [PubMed: 17520423]
48. Johansson K, Ingvar C, Albertsson M, Ekdahl C. Arm Lymphoedema, Shoulder Mobility and Muscle Strength after Breast Cancer Treatment – A Prospective 2-year Study. *Adv Physiother*. 2001; 3:55–66.
49. Bennett Britton TM, Buczacki SJ, Turner CL, Vowler SL, Pain SJ, Purushotham AD. Venous changes and lymphoedema 4 years after axillary surgery for breast cancer. *Br J Surg*. 2007; 94(7):833–834. [PubMed: 17335123]
50. Kosir MA, Rymal C, Koppolu P, Hryniuk L, Darga L, Du W, Rice V, Mood D, Shakoor S, Wang W, Bedoyan J, Aref A, Biernat L, Northouse L. Surgical outcomes after breast cancer surgery: measuring acute lymphedema. *J Surg Res*. 2001; 95(2):147–151. [PubMed: 11162038]
51. Pain SJ, Vowler S, Purushotham AD. Axillary vein abnormalities contribute to development of lymphoedema after surgery for breast cancer. *Br J Surg*. 2005; 92(3):311–315. [PubMed: 15672436]
52. Quinlan E, Thomas-MacLean R, Hack T, Kwan W, Miedema B, Tatemichi S, Towers A, Tilley A. The impact of breast cancer among Canadian women: disability and productivity. *Work*. 2009; 34(3):285–296. [PubMed: 20037243]
53. Edwards TL. Prevalence and aetiology of lymphoedema after breast cancer treatment in southern Tasmania. *Aust N Z J Surg*. 2000; 70(6):412–418. [PubMed: 10843395]
54. Tengrup I, Tennvall-Nittby L, Christiansson I, Laurin M. Arm morbidity after breast-conserving therapy for breast cancer. *Acta Oncol*. 2000; 39(3):393–397. [PubMed: 10987237]
55. Armer JM, Stewart BR. Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months. *Lymphology*. 2010; 43(3):118–127. [PubMed: 21226414]
56. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A note on competing risks in survival data analysis. *Br J Cancer*. 2004; 91(7):1229–1235. [PubMed: 15305188]
57. Stout NL, Pfalzer LA, Springer B, Levy E, McGarvey CL, Danoff JV, Gerber LH, Soballe PW. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. *Phys Ther*. 2011; 92(1):152–163. [PubMed: 21921254]
58. Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. *BMJ*. 2010; 340:b5396. [PubMed: 20068255]
59. Rockson SG. Precipitating factors in lymphedema: myths and realities. *Cancer*. 1998; 83(12 Suppl American):2814–2816. [PubMed: 9874403]
60. Hayes S, Cornish B, Newman B. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. *Breast Cancer Res Treat*. 2005; 89(3):221–226. [PubMed: 15754119]
61. O'Toole J, Jammallo LS, Miller CL, Skolny MN, Specht MC, Taghian AG. Screening for Breast Cancer-Related Lymphedema: The Need for Standardization. *Oncologist*. 2013
62. Mahamaneerat WK, Shyu CR, Stewart BR, Armer JM. Breast cancer treatment, BMI, post-op swelling/lymphoedema. *J Lymphoedema*. 2008; 3(2):38–44. [PubMed: 20657749]


63. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, Miller LT, Demichele A, Solin LJ. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. *J Clin Oncol*. 2009; 27(3):390–397. [PubMed: 19064976]
64. Clark B, Sitzia J, Harlow W. Incidence and Risk of Arm Oedema Following Treatment for Breast Cancer: A Three-Year Follow-up Study. *Q J Med*. 2005; 98:343–348.
65. Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. *Cancer*. 1998; 83(12 Suppl American):2776–2781. [PubMed: 9874397]
66. Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. *J Natl Cancer Inst*. 2001; 93(2):96–111. [PubMed: 11208879]
67. Petrek JA, Senie RT, Peters M, Rosen PP. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. *Cancer*. 2001; 92(6):1368–1377. [PubMed: 11745212]



No. at risk: 1173    961    635    407    205    81

**Figure 1.**  
Cumulative incidence of RVC ≥ 10%





**Figure 2.** Cumulative incidence of progression to RVC ≥ 10% among patients who had an RVC measurement in the 3%-<5% category occurring > 3 months after surgery and among patients who had a measurement in the 5%-<10% category at > 3 months after surgery.

**Table 1**

Clinical and pathologic characteristics of patient cohort

	Median (Range)	n = 1173 (100%)
<b>Patient Characteristics</b>		
Age at diagnosis, years	56 (24–89)	-
BMI at diagnosis, kg/m <sup>2</sup>	26.3 (16.5–55.7)	-
<b>Pathologic Characteristics</b>		
Invasive Carcinoma	-	998 (85%)
Ductal Carcinoma in Situ (DCIS)	-	175 (15%)
Invasive tumor size, cm	1.4 (0.05–12.0)	-
<b>Breast Surgery</b>		
Lumpectomy	-	864 (74%)
Mastectomy	-	309 (26%)
<b>Axillary Surgery</b>		
None	-	159 (14%)
SLNB	-	722 (62%)
ALND	-	292 (25%)
#LN's removed, SLNB	2 (1–7)	-
#LN's removed, ALND	16 (3–43)	-
# Positive LN's, ALND	2 (0–39)	-
<b>Radiation Therapy</b>		
None	-	214 (18%)
Breast/ chest wall only	-	712 (61%)
Breast/ chest wall + nodal radiation	-	237 (20%)
Unknown fields	-	10 (1%)
<b>Neoadjuvant Chemotherapy</b>		
Yes	-	114 (10%)
No	-	1059 (90%)
<b>Adjuvant Chemotherapy</b>		
Yes	--	431 (37%)
No	--	742 (63%)
<b>Hormonal Therapy</b>		
Yes	-	876 (75%)
No	-	297 (25%)

Abbreviations: BMI = Body Mass Index, ALND = Axillary lymph node dissection, SLNB = Sentinel lymph node biopsy, LN = lymph node

**Table 2**

2-year cumulative incidence of RVC 10% according to type of axillary surgery and radiation therapy

	N	2-year cumulative incidence	95% Confidence Interval	
No axillary surgery	160	2.40%	0.77%	7.32%
SLNB, no nodal radiation	678	2.00%	1.13%	3.52%
SLNB with nodal radiation	44	6.08%	1.49%	23.04%
ALND, no nodal radiation	92	10.21%	5.18%	19.60%
ALND with nodal radiation	194	18.07%	12.61%	25.54%

Abbreviations: SLNB = sentinel lymph node biopsy, ALND = axillary lymph node dissection

**Table 3**

Univariate analysis of risk factors associated with progression to RVC 10% at >3 months post-operative

	Hazard Ratio	95% Confidence Interval	P Value	
<b>Patient Characteristics</b>				
Age at diagnosis	1.01	0.99	1.03	0.64
BMI at diagnosis	1.07	1.03	1.10	0.0002
<b>Surgical Characteristics</b>				
Mastectomy vs. lumpectomy	1.89	1.18	3.01	0.0079
SLNB vs. no axillary surgery	0.70	0.28	1.74	0.44
ALND vs. SLNB	6.59	3.95	11.0	<0.0001
# LN's removed	1.09	1.07	1.11	<0.0001
# Positive LN's	1.08	1.05	1.11	<0.0001
<b>Systemic Therapy</b>				
Adjuvant chemotherapy	2.08	1.32	3.30	0.0017
Hormonal Therapy	1.14	0.66	1.95	0.64
<b>Radiation Therapy</b>				
Breast/ chest wall only	0.63	0.34	1.20	0.16
Breast/ chest wall +nodal radiation	3.38	1.82	6.29	0.0001
<b>Arm measurements 3 Months Post-op</b>				
3-<5% RVC	3.18	1.63	6.19	0.0007
5-<10% RVC	7.49	4.29	13.1	<0.0001
10% RVC	16.7	6.53	42.6	<0.0001
<b>Arm measurements &gt;3 Months Post-op</b>				
3-<5% RVC	2.25	1.33	3.81	0.0025
5-<10% RVC	5.43	3.26	9.05	<0.0001

Abbreviations: BMI = Body Mass Index, SLNB = Sentinel lymph node biopsy, ALND = Axillary lymph node dissection, LN = lymph node, RVC = Relative Volume Change

\* Age, BMI, # LN's removed and # positive LN's analyzed as continuous variables

\* Reference group for arm measurements is <+3% RVC during that time period ( 3 or >3 months post-operative)



**Table 4**

Multivariable analysis of risk factors associated with progression to RVC 10% at &gt;3 months post-operative

	Hazard Ratio	95% Confidence Interval		P Value
<b>Patient Characteristics</b>				
BMI at diagnosis	1.06	1.02	1.10	0.0028
<b>Surgical Characteristics</b>				
ALND	4.08	2.49	6.68	<0.0001
<b>Arm measurements 3 Months Post-op</b>				
3-<5% RVC	2.52	1.29	4.94	0.007
5-<10% RVC	3.24	1.80	5.84	<0.0001
10% RVC	4.70	1.24	17.8	0.023
<b>Arm measurements &gt;3 Months Post-op</b>				
3-<5% RVC	1.55	0.92	2.61	0.10
5-<10% RVC	2.97	1.75	5.04	<0.0001
# of measurements per year	1.29	1.16	1.44	<0.0001

Abbreviations: BMI = Body Mass Index, ALND = Axillary lymph node dissection, RVC = Relative Volume Change

\* Reference group for arm measurements is <3% RVC during that time period ( 3 or >3 months post-operative)